Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Phase 1

A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment

NCT07933848 · tracked via the Priya Life Science USA tracker
Sponsor
Phase
Phase 1
Started
2026-11-17
Last updated
2026-11-12

Condition(s) studied

Renal ImpairmentHealthy Adults

Investigational drug(s) / intervention(s)

Prifetrastat →

Prifetrastat: Prifetrastat administered by mouth as a single dose.

Study summary

The primary purpose of this study is to understand how the body processes the study medicine, called prifetrastat, in people with renal impairment compared to healthy people with normal kidney function. Renal impairment means that a person has worse kidney function than normal. The study will also look at the safety and tolerability of prifetrastat in people with renal impairment compared to healthy people with normal kidney function.

This study is seeking participants who:

* Have moderate or severe renal impairment or
* Healthy people with normal kidney function

All participants in this study will receive a single dose of prifetrastat. The study medicine will be given by mouth at the study clinic. We will compare experiences of people with renal impairment and healthy people with normal kidney function.

Participants will take part in this study for about 2 months. During this time, they will stay at the study clinic for 8 to 16 days.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
Accepted
Inclusion Criteria * Female of nonchildbearing potential or males, 18 to 90 years of age at screening. * Body mass index (BMI) of 16-40 kg/m2; and a total body weight \>50 kg (110 lb). * Stable renal function that matches the classification of either moderate renal impairment, severe renal impairment, or normal renal function. Exclusion Criteria * Any condition possibly affecting drug absorption * Acute renal disease * Renal allograft recipient * Renal transplant recipient * Urinary incontinence without catheterization * Current use of any prohibited concomitant medication(s)

Primary outcome measure(s)

  • Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Prifetrastat — Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose
  • Maximum Observed Plasma Concentration (Cmax) of Prifetrastat — Pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 120, 168, 216, 264, 312, and 360 hours post-dose

Trial sites (3)

FacilityCityRegionStatus
Floridian Clinical Research Miami Lakes Florida
Genesis Clinical Research, LLC Tampa Florida
Nucleus Network Minneapolis Saint Paul Minnesota
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07933848 on ClinicalTrials.gov ↗ ← All trials in the USA